8-K: Lantheus Q3 2025 Results & Leadership Shake-Up

Lantheus Holdings reported mixed third-quarter 2025 financial results, including a significant drop in GAAP earnings, alongside a major leadership transition with CEO Brian Markison's retirement and the appointment of Mary Anne Heino as Executive Chair and Interim CEO.

Summary

• Reported Q3 2025 worldwide revenue of $384.0 million, a 1.4% increase from Q3 2024.
• GAAP fully diluted earnings per share decreased 77.1% to $0.41, from $1.79 in Q3 2024.
• Adjusted fully diluted earnings per share (non-GAAP) decreased 25.3% to $1.27, from $1.70 in Q3 2024.
• Sales of PYLARIFY were $240.6 million, a decrease of 7.4%.
• Sales of DEFINITY were $81.8 million, an increase of 6.3%.
• CEO Brian Markison will retire effective December 31, 2025, and will serve as a strategic advisor through at least March 31, 2026.
• Mary Anne Heino, current Chair of the Board and former CEO, has been appointed Executive Chair effective November 7, 2025, and Interim CEO effective January 1, 2026.
• President Paul Blanchfield is leaving the company effective November 7, 2025.
• Amanda Morgan will return as Chief Commercial Officer, reporting to Ms. Heino.
• Completed the acquisition of Life Molecular Imaging in July, expanding its nuclear medicine portfolio.
• Repurchased $100 million of common stock in Q3 2025.
• Updated full-year 2025 revenue guidance to $1.49 billion $1.51 billion and adjusted fully diluted EPS guidance to $5.50 $5.65.
• Announced PDUFA target action dates for LNTH-2501 (March 29, 2026), MK-6240 (August 13, 2026), and a new formulation of piflufolastat F 18 PSMA PET imaging agent (March 6, 2026).

Sentiment

Score: 4

Explanation: While revenue saw a slight increase and the pipeline shows promise with multiple PDUFA dates, the significant decline in GAAP and adjusted earnings per share, coupled with a decrease in sales of the flagship product PYLARIFY, indicates underperformance in the quarter. The leadership transition, while bringing back an experienced former CEO, introduces uncertainty and the departure of the President adds to this. The updated guidance, while slightly raising the lower end of revenue, slightly lowered the upper end of EPS, reflecting a mixed outlook.

Positives

• Worldwide revenue increased by 1.4% to $384.0 million in Q3 2025 compared to Q3 2024.
• DEFINITY sales increased by 6.3% to $81.8 million.
• Successfully closed the acquisition of Life Molecular Imaging in July, immediately expanding the nearand long-term growth profile and commercial portfolio.
• Secured an exclusive licensing agreement with GE HealthCare for piflufolastat F 18 in Japan, including an upfront license fee, development milestones, and tiered royalties.
• Advanced its radiopharmaceutical pipeline with three PDUFA target action dates set for March 29, 2026 (LNTH-2501), August 13, 2026 (MK-6240), and March 6, 2026 (new piflufolastat F 18 formulation).
• Repurchased $100 million of common stock in Q3 2025, demonstrating commitment to shareholder returns.
• Maintained access to up to $750.0 million from a revolving line of credit.
• Full year 2025 revenue guidance was slightly raised at the lower end, from $1.475 billion to $1.49 billion.

Negatives

• GAAP net income decreased by 78.8% to $27.8 million in Q3 2025 compared to $131.1 million in Q3 2024.
• GAAP fully diluted earnings per share decreased by 77.1% to $0.41 in Q3 2025 compared to $1.79 in Q3 2024.
• Adjusted net income (non-GAAP) decreased by 30.9% to $85.7 million.
• Adjusted fully diluted earnings per share (non-GAAP) decreased by 25.3% to $1.27.
• PYLARIFY sales decreased by 7.4% to $240.6 million.
• Operating income decreased by 67.4% to $43.6 million.
• Adjusted operating income (non-GAAP) decreased by 27.6% to $119.6 million.
• Cash and cash equivalents significantly decreased to $382.0 million at September 30, 2025, from $912.8 million at December 31, 2024, primarily due to acquisitions and share repurchases.
• The full-year 2025 adjusted fully diluted EPS guidance range was slightly lowered at the higher end, from $5.70 to $5.65.
• Significant turnover in leadership with the retirement of the CEO and departure of the President.

Risks

• Continued market expansion and penetration for established commercial products (PYLARIFY, DEFINITY, Neuraceq) in a competitive environment and the ability to clinically and commercially differentiate products.
• Ability to have third parties manufacture products and the ability to manufacture DEFINITY in-house, in amounts and at times needed.
• Availability of raw materials, key components, equipment, and PET scanners for products and product candidates.
• Ability to obtain FDA approval for the new formulation of the F-18 PSMA PET imaging agent, complete technology transfer across manufacturing facilities, and obtain adequate coding, coverage, and payment, including transitional pass-through payment status.
• Ability to satisfy obligations under existing clinical development partnerships using MK-6240 or NAV-4694 and to further develop and commercialize them.
• Ability to successfully integrate acquisitions, including Life Molecular Imaging and Evergreen, with potential for unforeseen expenses, liabilities, IT system integration challenges, and talent retention issues.
• Ability to complete the sale of the SPECT business to SHINE Technologies, LLC on proposed terms and timeline, including regulatory approvals and other closing conditions.
• Ability to obtain FDA approval for LNTH-2501 and PNT2003, and success in patent litigation associated with PNT2003.
• Cost, efforts, and timing for clinical development, regulatory approval, adequate coding, coverage, payment, and successful commercialization of product candidates and new clinical applications.
• Ability to identify opportunities to collaborate with strategic partners and acquire/in-license additional diagnostic and therapeutic product opportunities.
• Effect that changes to management, including turnover in leadership and senior management team, could have on the business.
• General risks and uncertainties discussed in SEC filings (Form 10-K and 10-Q).

Future Outlook

The company anticipates continued advancement in its radiopharmaceutical leadership, focusing on PYLARIFY commercial execution and broader strategic diversification, including a new PSMA PET formulation. It expects to expand its portfolio of late-stage assets and high potential early-stage candidates, successfully integrate recent acquisitions (Life Molecular Imaging and Evergreen), and complete the divestiture of its SPECT business. The company has provided updated full-year 2025 guidance, projecting revenue between $1.49 billion and $1.51 billion and adjusted fully diluted EPS between $5.50 and $5.65. Significant pipeline progress is expected with three PDUFA target action dates in early to mid-2026 for LNTH-2501, MK-6240, and a new piflufolastat F 18 formulation.

Management Comments

• "Lantheus third quarter results underscore the strength of our strategy and the dedication of our team as we continue to advance our leadership in radiopharmaceuticals." Brian Markison, CEO.
• "As I look ahead to my planned retirement at year-end, announced separately today, I am confident Lantheus is set up for continued success." Brian Markison, CEO.
• "On the heels of this quarter's solid results, Lantheus is preparing for the next chapter of our prostate cancer franchise by prioritizing PYLARIFY commercial execution with focus and discipline, while advancing our broader strategic diversification plan, including our new PSMA PET formulation." Brian Markison, CEO.
• "Together with the combined expertise of the Lantheus team and our talented Life Molecular Imaging and Evergreen colleagues, we remain united in our purpose to Find, Fight and Follow disease to deliver better patient outcomes." Brian Markison, CEO.
• "His valuable insights and contributions strengthened Lantheus' leadership position at the forefront of radiopharmaceutical innovation and have positioned the Company for future growth opportunities with multiple near-term potential FDA market approvals and a strong pipeline of diagnostic and therapeutic candidates." Julie McHugh, Lead Independent Director, on Brian Markison.
• "The Board and management team are committed to ensuring a smooth transition, and we look forward to working closely with Mary Anne throughout this process. Her extensive experience, deep familiarity with our business, strategic vision and proven track record of successful commercialization make her uniquely equipped to continue effectively executing our existing strategy and building momentum during this transition period." Julie McHugh, Lead Independent Director, on Mary Anne Heino.
• "I am excited to take on the role of Executive Chairperson and honored to step in as interim CEO following Brian's retirement. I look forward to partnering with Brian, Amanda, and our talented team during this transition as we continue to focus on commercial execution, expand the reach of our innovative solutions, and maximize the success of our upcoming expected product approvals, including the new formulation of our market-leading PSMA PET imaging agent." Mary Anne Heino.
• "Serving on the Board and leading such a dedicated group of employees at Lantheus as CEO has been one of the most rewarding chapters of my career. I am proud of the progress we've made to solidify Lantheus' position as the partner of choice in nuclear medicine, and I'm energized by the Company's exciting opportunities that lie ahead." Brian Markison.

Industry Context

Lantheus operates in the rapidly evolving radiopharmaceutical sector, which is seeing significant innovation in diagnostic and therapeutic applications, particularly in oncology (prostate cancer, neuroendocrine tumors) and neurology (Alzheimer's disease). The company's focus on PSMA PET imaging agents for prostate cancer (PYLARIFY and its new formulation) positions it in a growing market segment. The acquisition of Life Molecular Imaging and pipeline advancements in tau-targeted PET imaging (MK-6240) align with the increasing demand for early and accurate Alzheimer's diagnostics. The licensing deal with GE HealthCare for the Japanese market indicates a strategic move to expand global reach for its key products, leveraging established partners. The leadership transition, while significant, brings back a former CEO with a proven track record in the radiopharmaceutical space, which could provide stability during a period of strategic growth and pipeline maturation.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Mary Anne Heino previously entered into an indemnification agreement with the Company in connection with her service as a member of the Board, which remains in effect. No other related party transactions between the Company and Ms. Heino were disclosed.

Stakeholder Impact

• Shareholders: Mixed impact. Share repurchase program is positive, but significant decline in GAAP EPS and PYLARIFY sales are concerning. Leadership transition introduces uncertainty but also brings back an experienced former CEO. Pipeline progress offers future growth potential.
• Employees: Significant leadership changes (CEO, President departures, Interim CEO appointment) could create uncertainty but also new opportunities under the incoming leadership. The integration of acquired companies (Life Molecular Imaging, Evergreen) may lead to organizational restructuring.
• Customers: Continued focus on commercial execution for PYLARIFY and advancements in the radiopharmaceutical pipeline (new PSMA formulation, MK-6240, LNTH-2501) aim to provide enhanced diagnostic and therapeutic solutions, potentially improving patient outcomes and access.
• Suppliers: Ongoing need for raw materials and key components for product manufacturing, as highlighted in risk factors, indicates continued reliance on supplier relationships.
• Creditors: The company maintains access to a $750.0 million revolving line of credit, indicating liquidity, but cash reserves have decreased due to acquisitions and share repurchases.

Next Steps

• Board to conduct a comprehensive search for a new Chief Executive Officer.
• Brian Markison to serve as a strategic advisor to the Company through at least March 31, 2026.
• Mary Anne Heino to lead the company as Interim CEO starting January 1, 2026.
• Focus on PYLARIFY commercial execution and advancing the broader strategic diversification plan, including the new PSMA PET formulation.
• Prepare for potential FDA market approvals for LNTH-2501 (March 29, 2026), MK-6240 (August 13, 2026), and the new piflufolastat F 18 PSMA PET imaging agent formulation (March 6, 2026).
• Continue integration of Life Molecular Imaging and Evergreen acquisitions.
• Complete the sale of the SPECT business to SHINE Technologies, LLC.
• Host a conference call and webcast on November 6, 2025, at 8:00 a.m. ET to discuss results and guidance.

Key Dates

Recommendation

The Q3 2025 financial results present a mixed picture, with revenue growth but a significant decline in GAAP earnings and a drop in sales for the key product PYLARIFY. This indicates operational challenges despite strategic acquisitions and pipeline advancements. The leadership transition, while bringing back an experienced former CEO, introduces a period of uncertainty and the departure of the President adds to this. While the pipeline has promising PDUFA dates, their commercial success is not guaranteed. The share repurchase program is a positive signal for shareholder value, but the overall financial performance and leadership changes suggest a "hold" position until there is clearer evidence of improved operational execution and successful integration of new leadership and acquisitions. Investors should monitor the new CEO search, the performance of PYLARIFY, and the commercialization of pipeline products.

Keywords

Radiopharmaceuticals, Prostate Cancer, Alzheimer's Disease, Neuroendocrine Tumors, PSMA PET Imaging, PYLARIFY, DEFINITY, MK-6240, LNTH-2501, Life Molecular Imaging, CEO Retirement, Interim CEO, Financial Results, Q3 2025, Lantheus Holdings, LNTH, FDA Approval, PDUFA, Acquisition, Share Repurchase